Exploring the impacts of Pycnogenol on pentraxin-3 levels in the heart tissue of rats administered with gentamicin

Abstract

Aims: The present study explored if pentraxin-3 (PTX-3) levels, which would be boosted due to cardiac damage by gentamicin, can be regressed thanks to Pycnogenol, which was also previously shown to have desirable impacts on cardiovascular diseases. Methods: In the study, we recruited 28 8-10-week-old male Sprague-Dawley rats into four groups: control, gentamicin, gentamycin+Pycnogenol, and Pycnogenol. We stained the tissue samples with hematoxylin-eosin and Masson’s trichome dye for histopathological analysis. Then, malondialdehyde (MDA) levels were measured using the spectrophotometric technique. In addition, we measured PTX-3 levels in the heart tissues by an immunohistochemical method. Results: We discovered the heart tissue samples of the rats in the control and Pycnogenol groups were histologically normal. As well as mononuclear cell increase and degeneration of cardiac muscle cells, we observed mild congestion in the gentamicin group compared to the control group. Despite more significant damage to the heart tissue in the gentamicin+Pycnogenol group compared to the control group, we found that the histopathological damage regressed in this group compared to the gentamicin group. While PTX-3 immunoreactivity was similar between the control and Pycnogenol groups, it was significantly elevated in the gentamicin group compared to the control group (p < 0.001). Moreover, the gentamicin+Pycnogenol group had decreased PTX-3 immunoreactivity than the gentamicin group. While MDA values followed a similar pattern between the control and Pycnogenol groups, these values were found to be significantly increased in the gentamicin group compared to the control group (p < 0.001). These values, however, were decreased in the gentamicin+Pycnogenol group compared to the gentamicin group. Conclusion: In a nutshell, the present study was able to demonstrate that gentamicin may lead to cardiac damage by boosting PTX-3 levels and that the damage can be regressed thanks to the Pycnogenol treatment.

Keywords

• Pycnogenol
• Gentamicin
• Pentraxin 3 (PTX-3)
• Malondialdehyde (MDA)
• Cardiotoxicity

References

1. D’Andrea G. Pycnogenol: a blend of procyanidins with multifaceted therapeutic applications? Fitoterapia. 2010;81(7):724-736.
2. Rezzani R, Porteri E, De Ciuceis C, et al. Effects of melatonin and pycnogenol on small artery structure and function in spontaneously hypertensive rats. Hypertension. 2010;55(6):1373-1380.
3. Park CM, Kim HY, Jeon D, et al. Anti-fibrotic effect of Pycnogenol® in a polyhexamethylene guanidine-treated mouse model. Respir Physiol Neurobiol. 2022;296(1):103802.
4. Simpson T, Kure C, Stough C. Assessing the efficacy and mechanisms of pycnogenol® on cognitive aging from in vitro animal and human studies. Front Pharmacol. 2019;10(1):694.
5. Zhang Z, Tong X, Wei YL, Zhao L, Xu JY, Qin LQ. Effect of Pycnogenol supplementation on blood pressure: a systematic review and meta-analysis. Iran J Public Health. 2018;47(6):779-787.
6. Al-Kuraishy HM, Al-Gareeb AI, Rasheed HA. Antioxidant and anti-inflammatory effects of curcumin contribute into attenuation of acute gentamicin-induced nephrotoxicity in rats. Asian J Pharmaceutical Clin Res. 2019;12(3):466-468.
7. Adams HR. Direct myocardial depressant effects of gentamicin. Eur J Pharmacol. 1975;30(2):272.
8. Adams HR. Cardiovascular depressant effects of neomycin and gentamicin in rhesus monkey. Br J Pharmacol. 1975;54(4):453.

9. Cohen LS, Wechsler AS, Mitchell JH, Glick G. Depression of cardiac function by streptomycin and other antimicrobial agents. Am J Cardiol. 1970;26(5):505.
10. Garlanda C, Bottazzi B, Magrini E, Inforzato A, Mantovani A. PTX3, a humoral pattern recognition molecule, in innate immunity, tissue repair, and cancer. Physiol Rev. 2018;98(2):623-639.
11. Doni A, Musso T, Morone D,et al. An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode. J Exp Med. 2015;212(6):905-925.
12. Breviario F, d’Aniello EM, Golay J, et al. Interleukin-1-inducible genes in endothelial cells. cloning of a new gene related to c-reactive protein and serum amyloid p component. J Biol Chem. 1992;267(31):22190-22197.
13. Vouret-Craviari V, Matteucci C, Peri G, Poli G, Introna M, Mantovani A. Expression of a long Pentraxin, PTX3, by monocytes exposed to the mycobacterial cell wall component lipoarabinomannan. Infect Immun. 1997;65(4):1345-1350.
14. Brunetta E, Folci M, Bottazzi B, et al. Macrophage expression and prognostic significance of the long Pentraxin PTX3 in COVID-19. Nat Immunol. 2021;22(1):19-24.
15. Caironi P, Masson S, Mauri T, et al. Pentraxin 3 in patients with severe sepsis or shock: the ALBIOS trial. Eur J Clin Investig. 2017;7(1):73-83.
16. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM. Associations of Pentraxin 3 with cardiovascular disease and all-cause death: the cardiovascular health study. Arterioscler Thromb Vasc Biol. 2009;29(4):594-599.
17. Latini R, Maggioni AP, Peri G, et al. Prognostic significance of the long Pentraxin PTX3 in acute myocardial infarction. Circulation. 2004;110(16):2349-2354.
18. Porte R, Davoudian S, Asgari F,et al. The long Pentraxin PTX3 as a humoral innate immunity functional player and biomarker of infections and sepsis. Front Immunol. 2019;10(1):794.
19. Miri S, Safari T, Komeili GR,et al. Sex difference in gentamicin-induced nephrotoxicity: influence of L-arginine in rat model. Int J Prev Med. 2018;9(1):108.
20. Atta MS, Farrag FA, Almadaly EA,et al. Transcriptomic and biochemical effects of Pycnogenol in ameliorating heat stress-related oxidative alterations in rats. J Thermal Biol. 2020;93(1):102683.
21. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29(4):577-580.
22. Nadire Eser and others, Ameliorative effects of garlic oil on FNDC5 and irisin sensitivity in liver of streptozotocin-induced diabetic rats. J Pharm Pharmacol. 2021;73(6):824-834
23. Kuloglu T, Aydin S, Eren MN, et al. Irisin: a potentially candidate marker for myocardial infarction. Peptides. 2014;55(1):85-91
24. Turk A, Ulas M, Karadag A, Kocaman N, Onalan E, Kuloglu T. The effects of N-acetylcysteine on transient receptor potential melastatin 2 channels activation and expression in testicular tissue of diabetic rats. Cureus. 2023;15(5):e38661.
25. Tokac M, Bacanli M, Dumlu EG, et al. The ameliorative effects of Pycnogenol®on liver ischemia-reperfusion injury in rats. Turk J Pharm Sci. 2017;14(3):257-263.
26. Verlaet A, Van der Bolt N, Meijer B, et al. Toll-like receptor-dependent immunomodulatory activity of Pycnogenol®. Nutrients. 2019:11(2):214.
27. Becit M, Aydin S. An in vitro study on the interactions of Pycnogenol® with cisplatin in human cervical cancer cells. Turk J Pharm Sci. 2020;17(1):1-6.
28. Harati K, Slodnik P, Chromik AM, et al. Pro-apoptotic effects of pycnogenol on HT1080 human fibrosarcoma Cells. Int J Oncol. 2015;46(4):1629-1636.
29. Devaraj S, Vega-López S, Kaul N, Schönlau F, Rohdewald P, Jialal I. Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile. Lipids. 2002;37(10):931–934.
30. Belcaro G, Hu S, Cesarone MR, Dugall M. A controlled study shows daily intake of 50 mg of French Pine Bark Extract (Pycnogenol®) low- ers plasma reactive oxygen metabolites in healthy smokers. Minerva Med. 2013;104(4):439–446 .
31. Enseleit F, Sudano I, Périat D, et al. Ef- fects of Pycnogenol on endothelial function in patients with stable coronary artery disease: A double-blind, randomized, placebo-controlled, cross-over study. Eur Heart J. 2012;33(13):1589–1597 .
32. Ryan J, Croft K, Mori T, et al. An examination of the effects of the antioxidant Pycnogenol®on cognitive performance, serum lipid profile, endocrinological and oxidative stress biomarkers in an elderly population. J Psychopharmacol. 2008;22(5):553–562 .
33. Nishioka K , Hidaka T , Nakamura S , et al. Pyc- nogenol®, French maritime pine bark extract, augments endothelium-depen- dent vasodilation in humans. Hypertens Res. 2007;30(9):775–780 .
34. Fitzpatrick DF , Bing B , Rohdewald PJ . Endothelium-dependent vascular effects of pycnogenol. J Cardiovasc Pharmacol. 1998;32(4):509–515 .
35. Nebuloni M, Pasqualini F, Zerbi P, et al. PTX3 expression in the heart tissues of patients with myocardial infarction and infectious myocarditis. Cardiovasc Pathol. 2011;20(1):e27-35.
36. Zahir AS, Thanhtam T, Zaman K. Oxidative stress as a mechanism of chronic cadmium-induced hepatotoxicity and renal toxicity and protection by antioxidants. Toxicol Appl Pharmacol. 1999;154(1):256-263.
37. Li B, Webster TJ. Bacteria antibiotic resistance: new challenges and opportunities for implant-associated orthopedic infections. J Orthop Res. 2018;36(1):22-32.
38. De la Chapelle-Groz B, Athias P. Gentamicin causes the fast depression of action potential and contraction in cultured cardiocytes. Eur J Pharmacol. 1988;152(1-2):111-120.